$HCAT
Health Catalyst, Inc.

2024 Q3 Form 10-Q Financial Statement

#000163642224000120 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $76.35M $75.90M
YoY Change 3.5% 3.67%
Cost Of Revenue $42.12M $39.84M
YoY Change 1.17% 1.46%
Gross Profit $34.24M $36.06M
YoY Change 6.49% 6.23%
Gross Profit Margin 44.84% 47.51%
Selling, General & Admin $23.55M $27.11M
YoY Change -17.97% -10.68%
% of Gross Profit 68.79% 75.17%
Research & Development $14.19M $13.88M
YoY Change -19.66% -20.18%
% of Gross Profit 41.45% 38.5%
Depreciation & Amortization $3.100M $3.100M
YoY Change 0.0% -71.12%
% of Gross Profit 9.05% 8.6%
Operating Expenses $47.73M $51.65M
YoY Change -15.63% -11.68%
Operating Profit -$13.69M -$15.81M
YoY Change -44.32% -35.57%
Interest Expense -$1.514M $2.377M
YoY Change -157.35% 14.06%
% of Operating Profit
Other Income/Expense, Net -$123.0K -$16.00K
YoY Change 310.0% -366.67%
Pretax Income -$15.20M -$13.45M
YoY Change -30.81% -58.66%
Income Tax -$475.0K $70.00K
% Of Pretax Income
Net Earnings -$14.73M -$13.52M
YoY Change -33.16% -58.56%
Net Earnings / Revenue -19.29% -17.81%
Basic Earnings Per Share -$0.24 -$0.23
Diluted Earnings Per Share -$0.24 -$0.23
COMMON SHARES
Basic Shares Outstanding 60.47M shares 59.03M shares
Diluted Shares Outstanding 60.44M shares 59.30M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $387.3M $308.3M
YoY Change 11.38% -10.35%
Cash & Equivalents $328.3M $201.9M
Short-Term Investments $58.93M $106.4M
Other Short-Term Assets $18.51M $12.91M
YoY Change 25.92% -12.42%
Inventory
Prepaid Expenses
Receivables $51.65M $54.90M
Other Receivables $0.00 $0.00
Total Short-Term Assets $457.4M $376.1M
YoY Change 11.99% -8.49%
LONG-TERM ASSETS
Property, Plant & Equipment $27.91M $25.56M
YoY Change 6.94% -38.93%
Goodwill $234.4M $206.3M
YoY Change 26.03% 10.92%
Intangibles $76.46M $66.76M
YoY Change 6.2% -15.53%
Long-Term Investments
YoY Change
Other Assets $5.656M $5.413M
YoY Change 10.56% 6.49%
Total Long-Term Assets $355.6M $315.7M
YoY Change 16.81% 1.19%
TOTAL ASSETS
Total Short-Term Assets $457.4M $376.1M
Total Long-Term Assets $355.6M $315.7M
Total Assets $813.1M $691.7M
YoY Change 14.05% -4.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.28M $10.60M
YoY Change 125.67% 32.92%
Accrued Expenses $26.88M $21.38M
YoY Change 7.94% 11.03%
Deferred Revenue $52.20M $56.36M
YoY Change -1.63% -5.33%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $230.4M $228.8M
YoY Change
Total Short-Term Liabilities $323.8M $318.0M
YoY Change 284.29% 266.56%
LONG-TERM LIABILITIES
Long-Term Debt $114.6M $0.00
YoY Change -49.66% -100.0%
Other Long-Term Liabilities $3.395M $103.0K
YoY Change 4550.68% -99.46%
Total Long-Term Liabilities $118.0M $103.0K
YoY Change -48.18% -99.96%
TOTAL LIABILITIES
Total Short-Term Liabilities $323.8M $318.0M
Total Long-Term Liabilities $118.0M $103.0K
Total Liabilities $458.0M $334.7M
YoY Change 38.57% 0.51%
SHAREHOLDERS EQUITY
Retained Earnings -$1.166B -$1.151B
YoY Change 7.28% 8.12%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $355.0M $357.0M
YoY Change
Total Liabilities & Shareholders Equity $813.1M $691.7M
YoY Change 14.05% -4.31%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$14.73M -$13.52M
YoY Change -33.16% -58.56%
Depreciation, Depletion And Amortization $3.100M $3.100M
YoY Change 0.0% -71.12%
Cash From Operating Activities $6.208M $1.612M
YoY Change 99.61% -113.93%
INVESTING ACTIVITIES
Capital Expenditures $4.415M $4.328M
YoY Change 41.96% -9.87%
Acquisitions
YoY Change
Other Investing Activities $12.06M $2.545M
YoY Change -155.45% -197.4%
Cash From Investing Activities $7.646M -$1.783M
YoY Change -130.77% -75.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 112.5M 698.0K
YoY Change 10716.83% -41.93%
NET CHANGE
Cash From Operating Activities 6.208M 1.612M
Cash From Investing Activities 7.646M -1.783M
Cash From Financing Activities 112.5M 698.0K
Net Change In Cash 126.3M 527.0K
YoY Change -710.38% -102.96%
FREE CASH FLOW
Cash From Operating Activities $6.208M $1.612M
Capital Expenditures $4.415M $4.328M
Free Cash Flow $1.793M -$2.716M
YoY Change -96260954521600050.0% -83.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59304000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55977000 shares
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1431000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
130000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20236000 usd
us-gaap Net Income Loss
NetIncomeLoss
-34103000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-195000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
357002000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
425010000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-65803000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55976870 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58947653 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2020Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1000 usd
CY2020Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1000 usd
CY2020Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1000 usd
CY2024Q2 us-gaap Share Price
SharePrice
6.39
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 hcat Stockholders Vote
StockholdersVote
1 vote
us-gaap Dividends Cash
DividendsCash
0 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13516000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32613000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34103000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59303791 shares
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19804000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28513000 usd
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
78577000 usd
CY2024Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
894000 usd
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0 usd
CY2024Q2 us-gaap Senior Notes
SeniorNotes
228793000 usd
CY2023Q4 us-gaap Senior Notes
SeniorNotes
0 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
318024000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
89034000 usd
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
228034000 usd
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
51000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
77000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16540000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17676000 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
103000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
74000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
334718000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
334895000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58295491 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58295491 shares
CY2024Q2 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
1508437000 usd
CY2023Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
1484056000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1151273000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1117170000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-162000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
33000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
357002000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
366919000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
691720000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
701814000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
150625000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
147081000 usd
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
77742000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
31803000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
34966000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28755000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34672000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28927000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
47504000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
21182000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
21729000 usd
us-gaap Operating Expenses
OperatingExpenses
110667000 usd
us-gaap Operating Expenses
OperatingExpenses
138871000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-38619000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-69532000 usd
CY2024Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
2361000 usd
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
2090000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
4699000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
3883000 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-33920000 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-65649000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
183000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
154000 usd
us-gaap Net Income Loss
NetIncomeLoss
-34103000 usd
us-gaap Net Income Loss
NetIncomeLoss
-65803000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.18
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59304000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55977000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58948000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58948000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55732000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55732000 shares
us-gaap Net Income Loss
NetIncomeLoss
-34103000 usd
us-gaap Net Income Loss
NetIncomeLoss
-65803000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-168000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
455000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-11000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34298000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65359000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
357210000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1431000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
110000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9221000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
2584000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-13516000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-38000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
405146000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2206000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
170000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14867000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-32613000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
91000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
389867000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
366919000 usd
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
2584000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2206000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
897000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28921000 usd
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1808000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
444000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
389867000 usd
us-gaap Net Income Loss
NetIncomeLoss
-34103000 usd
us-gaap Net Income Loss
NetIncomeLoss
-65803000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
19804000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
28513000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
21182000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
21729000 usd
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
2200000 usd
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
2681000 usd
hcat Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-1434000 usd
hcat Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-1537000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
759000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
754000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3148000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3999000 usd
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
3438000 usd
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
1527000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
16000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
4000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
12000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
31000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2047000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5936000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1922000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-321000 usd
hcat Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities
-2380000 usd
hcat Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities
-1295000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
501000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4554000 usd
hcat Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1806000 usd
hcat Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1772000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11878000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17154000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
158200000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
188600000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
50197000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
165188000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
18659000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 usd
hcat Capitalized Of Internal Use Software
CapitalizedOfInternalUseSoftware
6287000 usd
hcat Capitalized Of Internal Use Software
CapitalizedOfInternalUseSoftware
6389000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
365000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
968000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
498000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
832000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
7000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
11000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
82201000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15234000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1431000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2206000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
130000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
897000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1808000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2033000 usd
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
0 usd
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
1310000 usd
us-gaap Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense
DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
432000 usd
us-gaap Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense
DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
408000 usd
hcat Capitalized Internal Use Software In Accounts Payable And Accrued Liabilities
CapitalizedInternalUseSoftwareInAccountsPayableAndAccruedLiabilities
216000 usd
hcat Capitalized Internal Use Software In Accounts Payable And Accrued Liabilities
CapitalizedInternalUseSoftwareInAccountsPayableAndAccruedLiabilities
295000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
105000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
46000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 segment
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
933000 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
13000 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
943000 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
27000 usd
CY2024Q2 us-gaap Advertising Expense
AdvertisingExpense
300000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
75902000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73213000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
150625000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
147081000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 segment
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2024Q2 us-gaap Goodwill
Goodwill
206295000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
190652000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
215618000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
148855000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
66763000 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7500000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7500000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
14800000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
15300000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
207493000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
134109000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
73384000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
58848000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
53069000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
33293000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27357000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25555000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25712000 usd
CY2024Q2 us-gaap Depreciation
Depreciation
3100000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
3200000 usd
us-gaap Depreciation
Depreciation
6400000 usd
us-gaap Depreciation
Depreciation
6400000 usd
CY2024Q2 us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
3600000 usd
CY2023Q2 us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
3200000 usd
us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
6400000 usd
us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
6600000 usd
CY2024Q2 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
2300000 usd
CY2023Q2 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
2100000 usd
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
4700000 usd
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
4300000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
303159000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
81000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
303078000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
311144000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
117000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
30000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
311231000 usd
CY2024Q2 us-gaap Interest Receivable
InterestReceivable
1200000 usd
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
900000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8456000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11680000 usd
CY2024Q2 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
345000 usd
CY2023Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
2355000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9247000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9247000 usd
CY2024Q2 hcat Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
18048000 usd
CY2023Q4 hcat Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
23282000 usd
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
666000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
777000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1294000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1574000 usd
CY2024Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
31000 usd
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
25000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
64000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
41000 usd
CY2024Q2 us-gaap Sublease Income
SubleaseIncome
339000 usd
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
189000 usd
us-gaap Sublease Income
SubleaseIncome
654000 usd
us-gaap Sublease Income
SubleaseIncome
627000 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
358000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
613000 usd
us-gaap Lease Cost
LeaseCost
704000 usd
us-gaap Lease Cost
LeaseCost
988000 usd
CY2024Q2 us-gaap Shares Issued
SharesIssued
60075178 shares
CY2024Q2 us-gaap Shares Outstanding
SharesOutstanding
60075178 shares
CY2023Q4 us-gaap Shares Issued
SharesIssued
58530880 shares
CY2023Q4 us-gaap Shares Outstanding
SharesOutstanding
58530880 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59303791 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55976870 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58947653 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55732211 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55732211 shares
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.18
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13213101 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14031923 shares
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8966000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14629000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19804000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28513000 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8966000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14629000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1396452 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.70
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
20764 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.26
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
293787 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.72
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1081901 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.93
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y6M
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1081901 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.93
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P3Y6M
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1081901 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.93
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y6M
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.005
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.002
CY2023Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
9600000 usd
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
21300000 usd
CY2024Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 usd
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 usd
CY2024Q2 hcat Contract With Customer Liability Revenue Recognized Percentage
ContractWithCustomerLiabilityRevenueRecognizedPercentage
0.44
CY2023Q2 hcat Contract With Customer Liability Revenue Recognized Percentage
ContractWithCustomerLiabilityRevenueRecognizedPercentage
0.50
hcat Contract With Customer Liability Revenue Recognized Percentage
ContractWithCustomerLiabilityRevenueRecognizedPercentage
0.28
hcat Contract With Customer Liability Revenue Recognized Percentage
ContractWithCustomerLiabilityRevenueRecognizedPercentage
0.30
CY2024Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
310400000 usd
CY2024Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.65
CY2024Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P24M
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 segment
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
75902000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73213000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
150625000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
147081000 usd
CY2024Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-13446000 usd
CY2023Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-32528000 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-33920000 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-65649000 usd
us-gaap Severance Costs1
SeveranceCosts1
2088000 usd
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001636422-24-000120-index-headers.html Edgar Link pending
0001636422-24-000120-index.html Edgar Link pending
0001636422-24-000120.txt Edgar Link pending
0001636422-24-000120-xbrl.zip Edgar Link pending
exhibit101healthcatalyst-c.htm Edgar Link pending
exhibit311-q22024xcertific.htm Edgar Link pending
exhibit312-q22024xcertific.htm Edgar Link pending
exhibit321-q22024xcertific.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hcat-20240630.htm Edgar Link pending
hcat-20240630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hcat-20240630_lab.xml Edgar Link unprocessable
hcat-20240630_pre.xml Edgar Link unprocessable
hcat-20240630_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
hcat-20240630_def.xml Edgar Link unprocessable
hcat-20240630_cal.xml Edgar Link unprocessable